Institutional investors purchased a net $90.2 thousand shares of MNOV during the quarter ended December 2012. This may signal that the smart money is gaining interest in this company as the 3.70% of shares outstanding that institutional investors hold is actually below the Biotechnology industry average.
| Other institutional | 2.02% |
| Individual stakeholders | 15.75% |
| Mutual fund holders | 1.68% |